Panel Finds Flawed Data in a Major Stem Cell Report
By NICHOLAS WADE,
New York Times
| 02. 28. 2007
An inquiry panel has found what it called "significantly flawed" data in a major stem cell paper published in Nature in 2002.
The article, which claimed stem cells isolated from an adult could change into all the major tissue types of the body, was seized on by opponents of abortion as showing that embryonic stem cell research was unnecessary since adult stem cells could provide all the predicted benefits.
The lead author of the article, Catherine Verfaillie, said yesterday that she had sent a letter to Nature stating that the flawed data should not be relied on but that they did not affect the article’s conclusions. She said the journal was resubmitting the article to the original referees for them to make their own assessment.
Problems with the article were first reported this month by New Scientist. Two writers for that magazine, Peter Aldhous and Eugenie Samuel Reich, noticed last year that a set of graphs in the Nature article was the same as that in an article by Dr. Verfaillie published in a different journal but ascribed to different...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
